Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Part D Formulary Coverage | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentIndependent HealthPolicy N/A

    Medicare Advantage Part D Formulary (Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs the Independent Health Medicare Advantage Part D drug formulary — which drugs are covered, applicable coverage restrictions (prior authorization, quantity limits, step therapy), and how members and prescribers can request exceptions or transition supplies.

    Policy Summary
    PayerIndependent Health
    PolicyMedicare Advantage Part D Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked 'PA' before dispensing to ensure coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12/1/2025formulary updated
    Monthlyupdates posted
    30dtransition supply
    34dLTC transition
    72/24hexception decision
    phone & webmember contacts

    Coverage Criteria & Formulary Rules

    General Formulary Coverage

    Covered when ALL of the following general conditions are met:

    General Coverage Conditions: (1) Drug is listed on the Independent Health Medicare Advantage Part D formulary; (2) The drug is medically necessary for the member; (3) The prescription is filled at an Independent Health network pharmacy; (4) Any listed coverage requirements or limits for the drug (e.g., prior authorization, quantity limits, step therapy, limited access) are met or an exception is approved.

    See formulary and plan administrative guidance for specifics on PA, QL, ST, LA and other flags.

    Transition and Emergency Supply

    Temporary coverage during transitions:

    Transition Supplies: (A) New or continuing members may receive a one-time 30-day transition supply at retail (or refills to total 30 days) while pursuing formulary exceptions or alternative therapies. (B) For long‑term care (LTC) residents or when access is limited, a 34‑day emergency supply (with refills to total 34 days) may be provided.30-day retail / 34-day LTC
    Policy Summary
    PayerIndependent Health
    PolicyMedicare Advantage Part D Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked 'PA' before dispensing to ensure coverage.
    SourceLink
    On This Page
    Coverage Criteria & Formulary RulesFormulary Listings & Code TablesPrior Authorization, Step Therapy & DocumentationStep Therapy RequirementsQuantity Limits by ProductSite-of-Care & Dispensing RestrictionsDefinitions & AbbreviationsBackground & Scope

    After authorizing the temporary supply the plan will notify the member and prescriber and describe options to request an exception or identify alternatives.

    Formulary coverage with utilization controls

    Formulary entries are covered per plan benefits but may require adherence to listed utilization controls; coverage depends on tier and Requirements/Limits annotations.

    Formulary coverage with utilization controls: Drug is covered when it is listed on the formulary and dispensed within plan limits; applicable utilization controls (PA, QL, ST, LA, EDS, BD) shown for the product must be satisfied.

    Specific product-level PA/QL/ST conditions and exceptions (for example, PA not required for oncologists on select fentanyl products) are stated on the formulary lines and in prior authorization guidance.

    Formulary coverage lines

    Drugs listed are covered under the formulary with the tier and any attached requirements/limits.

    Formulary coverage line: A product listed on the formulary is covered at the tier shown when the product‑specific conditions and Requirements/Limits (e.g., PA, QL, EDS, BD, LA, ST) for that product are met.

    Each product line in the formulary specifies its own tier and any requirement/limit flags that govern access and coverage.

    Formulary access requirements

    Coverage and access are tied to formulary tier and listed requirement/limit flags.

    Formulary entry access: Coverage and dispensing depend on the listed Tier and Requirements/Limits for the entry (for example: Prior Authorization (PA) required before coverage; Quantity Limit (QL) limits units per period; Step Therapy (ST) requires trial/failure of preferred drugs; Limited Access (LA) may restrict dispensing site).

    Providers must follow PA, meet QL, or satisfy ST/LA requirements listed for each formulary entry; failure to obtain required authorization may result in noncoverage.

    If a drug is not listed on the formulary and an exception is not granted, the plan will not provide coverage for that drug. Members should contact Member Services to confirm coverage status. If the drug is not covered, members may request a list of similar covered alternatives from Member Services and discuss those options with their prescriber, or they may request a formulary exception following the plan’s exception process.

    Formulary entries that are not explicitly listed — including specific formulations, strengths, or presentation types — may be excluded from coverage or subject to utilization controls such as Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), or Limited Access (LA). For drugs marked LA consult the Pharmacy Directory or Member Services for dispensing site restrictions. If a needed product is not on the formulary, providers or members can request a formulary exception per the plan’s exception procedures.

    This section does not list any explicit exclusion conditions beyond the general rule that non‑formulary products are not covered unless an exception is approved. Definitions and the meaning of requirement flags and symbols used throughout the formulary are provided elsewhere (see page VI).

    The document segment does not set out a standalone list of "not medically necessary" determinations. Medical necessity determinations are made in the context of the plan benefits and the formulary’s utilization controls (e.g., PA, QL, ST, LA) and via the exception process described in the formulary guidance.

    This portion of the formulary does not enumerate specific items as "Not Medically Necessary." Coverage decisions rely on whether the drug is on the formulary, meets the plan’s benefit and utilization-control requirements, or is approved through the plan’s exception process.

    Formulary Listings & Code Tables

    Antibacterial Productsmixed
    AMIKACIN_INJECTION_500MG_2MLamikacin sulfate injection solution 500 mg/2ml
    GENTAMICIN_IN_SALINE_IVgentamicin in saline intravenous solution (multiple concentrations)
    GENTAMICIN_SULFATE_EXTERNAL_CREAM_0.1%gentamicin sulfate external cream 0.1%
    GENTAMICIN_SULFATE_EXTERNAL_OINTMENT_0.1%gentamicin sulfate external ointment 0.1%
    GENTAMICIN_SULFATE_INJECTION_40MG_MLgentamicin sulfate injection solution 40 mg/ml
    NEOMYCIN_SULFATE_ORAL_TABLET_500MGneomycin sulfate oral tablet 500 mg
    STREPTOMYCIN_SULF_IM_INTRAMUSCULAR_1_GMstreptomycin sulfate intramuscular solution reconstituted 1 gm
    TOBRAMYCIN_SULFATE_INJECTIONtobramycin sulfate injection solution
    LINEZOLID_ORAL_SUSPENSION_100MG_5MLlinezolid oral suspension reconstituted 100 mg/5ml
    LINEZOLID_ORAL_TABLET_600_MGlinezolid oral tablet 600 mg
    1–10 of 16
    1/2
    Quantity Limit Codesmixed
    XIFAXAN_200_Q_LQL (9 EA per 3 days) for XIFAXAN 200 mg
    XIFAXAN_550_PAPA required for XIFAXAN 550 mg
    Oral Oncology Agents (sample)mixed
    ERLOTINIB_HCL_25_MGerlotinib hcl oral tablet 25 mg — QL (90 EA per 30 days)
    EVEROLIMUS_ORAL_TABLET_10_7.5_5_2.5_MGeverolimus oral tablet 10 mg, 7.5 mg, 5 mg, 2.5 mg — PA New Starts
    EXKIVITY_ORAL_CAPSULE_40_MGEXKIVITY ORAL CAPSULE 40 MG — PA New Starts; LA
    Oral Oncology Agents (additional sample)mixed
    OJJAARA_ORAL_TABLET_150_200_MGOJJAARA ORAL TABLET 150 mg, 200 mg — PA New Starts; LA
    PAZOPANIB_HCL_200_MGpazopanib hcl oral tablet 200 mg — PA New Starts
    PEMAZYRE_ORAL_TABLET_13.5_MGPEMAZYRE ORAL TABLET 13.5 mg — PA New Starts; LA
    Formulary Product Codes/Descriptionsmixed
    MOUNJARO_PEN_INJECTORSMOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR (multiple strengths) — PA; QL; EDS
    OZEMPIC_PEN_INJECTORSOZEMPIC SUBCUTANEOUS SOLUTION PEN-INJECTOR (multiple strengths) — PA; QL; EDS
    LANTUS_SOLOSTAR_100_UNIT_MLLANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML — EDS
    INSULIN_GLARGINE_MAX_SOLOSTAR_300_UNIT_MLinsulin glargine max solostar subcutaneous solution pen-injector 300 unit/ml — EDS
    INSULIN_LISPRO_PENinsulin lispro (1 unit dial) subcutaneous solution pen-injector 100 unit/ml — EDS
    OMNIPOD_DEVICESOMNIPOD devices and pods (various gens) — QL; EDS
    INSULIN_SYRINGES_30G_31Ginsulin syringe 30-gauge and 31-gauge
    Insulin Pen Productsmixed
    MOUNJARO_PENMOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR (multiple strengths)
    OZEMPIC_PENOZEMPIC SUBCUTANEOUS SOLUTION PEN-INJECTOR (multiple strengths)
    Insulin Pump/Pod Devicesmixed
    OMNIPOD_5_G7_KITS_PODSOMNIPOD 5 G7 kits and pods — QL
    OMNIPOD_DASH_GEN4_PODSOMNIPOD DASH pods (Gen 4) — QL
    Anticoagulants / Injectablesmixed
    DABIGATRAN_ETEXILATE_110_150_75_MGdabigatran etexilate mesylate oral capsule 110 mg, 150 mg, 75 mg
    ELIQUIS_STARTER_PACK_5_MGELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG
    ENOXAPARIN_INJECTION_PREFILLEDenoxaparin sodium injection solution prefilled syringe (multiple strengths)
    Hematopoietic Agentsmixed
    LEUKINE_INJECTION_250_MCGLEUKINE INJECTION SOLUTION RECONSTITUTED 250 MCG
    NEUPOGEN_INJECTION_300_MCG_MLNEUPOGEN INJECTION SOLUTION 300 MCG/ML; prefilled syringe options
    Cardiovascular Agentsmixed
    CANDESARTAN_CILEXETIL_TABLETScandesartan cilexetil oral tablet (multiple strengths) — EDS
    FILSPARI_200_400_MGFILSPARI ORAL TABLET 200 MG, 400 MG — PA; LA; QL (30 EA per 30 days)
    CORLANOR_ORAL_SOLUTION_5MG_5MLCORLANOR ORAL SOLUTION 5 mg/5ml — PA; Prior auth not required for cardiologists; EDS
    Formulary Items (no billing codes in this part)mixed
    PRALUENT_AUTO_INJECTORPRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML, 75 MG/ML — PA New Starts; EDS
    Formulary Items (continued)mixed
    REPATHA_PRODUCTSREPATHA PUSHTRONEX and prefilled syringe systems — PA New Starts; EDS
    Specialty Biologic Strengthsmixed
    DUPIXENT_PREFILLED_200_300MGDUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/1.14ML, 300 MG/2ML — PA
    Parenteral Nutrition / IV Solutionsmixed
    CLINISOL_SF_INTRAVENOUS_15%CLINISOL SF INTRAVENOUS SOLUTION 15% — BD
    Formulary Examplesmixed
    CLINIMIX_VARIANTSMultiple CLINIMIX and CLINIMIX/DEXTROSE formulations — BD
    Gastrointestinal Agents, Other (selected)mixed
    BYLVAY_PELLETSBYLVAY (PELLETS) ORAL CAPSULE SPRINKLE 200 MCG, 600 MCG — PA; LA
    XIFAXAN_200_MGXIFAXAN ORAL TABLET 200 MG — QL (9 EA per 3 days)
    XIFAXAN_550_MGXIFAXAN ORAL TABLET 550 MG — PA
    Gastrointestinal Agents (additional)mixed
    VOWST_ORAL_CAPSULEVOWST ORAL CAPSULE — PA; LA; QL (12 EA per 3 days)

    Prior Authorization, Step Therapy & Documentation

    Prior Authorization

    Prior Authorization Required — Certain drugs require PA

    Independent Health requires prior authorization (PA) for many drugs listed in the formulary. Drugs annotated with "PA" in the Requirements/Limits column require approval before dispensing; failure to obtain required PA may result in denial or noncoverage.

    • PA flags appear throughout the formulary for specialty, oncology, high‑tier, injectable and select oral agents.
    • PA may be specialty‑ or prescriber‑specific (for example, PA not required for oncologists, nephrologists, endocrinologists, cardiologists, dermatologists in select entries).
    • Drugs marked "PA New Starts" require PA for new therapy starts; ongoing therapy may have different handling.
    Prior Authorization

    PA required for listed specialty/oncology agents

    Many specialty and oral oncology agents are listed with PA or "PA New Starts." Providers must submit PA documentation for medical necessity, therapy pack/quantity limits (QL), andany limited‑access (LA) or extended‑day supply (EDS) indicators noted in the Requirements/Limits column.

    • Examples: numerous oral oncology agents and high‑tier specialty products are marked PA New Starts; many also have LA and QL flags.
    • When a drug lists LA, it may be available only at certain pharmacies — consult the Pharmacy Directory or Member Services.
    • EDS entries indicate extended day supply rules (e.g., 90‑ or 100‑day fills) which must be documented with the PA request when applicable.
    Prior Authorization

    Prior authorization flags — numerous drugs require PA/PA New Starts

    Prior authorization applies to many product types: injectables/specialty biologics, select antidiabetic and GLP‑1 injectables, anticonvulsants, dementia agents, immunologics, select topicals, and other high‑tier products. Check product‑specific Requirements/Limits for PA, QL, LA, ST, BD, or EDS indicators.

    • Examples: MOUNJARO, OZEMPIC, TRULICITY, several GLP‑1 and antidiabetic injectables are marked PA and QL; some injectables (Neupogen, Leukine, Retacrit, Udenyca, etc.) require PA.
    • Topical agents and dermatology entries may have PA with specialty exceptions (e.g., dermatologists or oncologists).
    • Anticonvulsants and select dementia/cholinesterase inhibitors may show PA New Starts, QL, EDS, or LA flags.
    Documentation Required

    Prescriber Statement for Exceptions & Documentation Expectations

    Prescribers must include supporting clinical documentation when requesting PA or an exception. For formulary or tiering exceptions, prescriber statements are required and Independent Health generally issues decisions within 72 hours of receiving supporting documentation (24 hours for expedited requests when clinically warranted).

    • Prescriber supporting statement must explain medical necessity for exception or waiver of PA/QL/ST.
    • Expedited (fast) decisions are available when waiting could seriously harm the enrollee; expedited decisions generally completed within 24 hours of prescriber documentation.
    • Contact Member Services or consult the Pharmacy Directory for submission instructions and specialty/pharmacy exceptions.
    Denial Risk

    Prior Authorization Denial Risk & Denial Triggers from Requirements/Limits

    Requests that do not meet the listed Requirements/Limits (PA, LA, QL, ST, BD, EDS) or lack required documentation may be denied. Noncompliance with PA or QL controls is a common denial trigger — obtain approvals and provide required clinical documentation to reduce denial risk.

    • Denials may occur when PA is not obtained prior to dispensing or when documentation does not support medical necessity.
    • PA or QL noncompliance may lead to noncoverage. Verify Requirements/Limits on the formulary before dispensing.
    • For drugs with BD or Part B/Part D uncertainty, submit use/setting details to determine coverage responsibility.
    Billing Rule

    Quantity Limit Enforcement & Documentation

    Quantity limits (QL) and therapy‑pack limits listed in the Requirements/Limits column must be honored. When submitting PA requests include quantity and pack‑specific justification; QL noncompliance without PA/documentation may result in denial.

    • Examples: QL entries (e.g., 2 ML per 28 days, 3 ML per 28 days, 120 EA per 30 days) are shown for GLP‑1s, migraine injectables, oncology therapy packs, and others.
    • Therapy pack / titration pack limits are indicated (therapy pack counts per 28/30/365 days) and require appropriate documentation for overrides.
    • Include exact requested quantity and rationale with PA submission to prevent processing delays.
    Step Therapy

    Step Therapy Requirement — sequences and exceptions

    Step therapy (ST) is used for select agents; drugs marked "ST" require trial and failure of specified preferred agents before coverage of non‑preferred alternatives. This formulary excerpt does not include step sequences — consult the full policy or contact Member Services for the required step sequences and alternatives.

    • ST appears for select products (example: febuxostat shows ST).
    • No explicit step therapy sequences are shown in this segment — providers must refer to the full policy or pharmacy documents for required first‑line agents and allowable exceptions.
    • Step therapy and tiering may vary by product; prescribers can request exceptions with supporting clinical rationale.

    Step Therapy Requirements

    Policy itemRequirement / Effect
    Drugs labeled 'ST' in the Requirements/Limits column
    Subject to step therapy — member must try and fail preferred agents listed by the plan before the ST drug is covered
    Drug group / flagRequired action
    Drugs marked 'ST'
    Prior trial(s) of preferred agent(s) per formulary step therapy must be documented before coverage of the alternative agent
    Product examplesUtilization control
    VALTOCO (nasal liquid) — various strengths
    Requirements/Limits = PA New Starts; prior authorization not required if prescribed by neurologists (specialty exception)
    DrugFormulary flag / implication
    Febuxostat (oral tablet 40 mg, 80 mg)
    Requirements/Limits = ST; step therapy requirement applies before coverage
    Access controlMeaning
    PA New Starts
    Prior authorization required for new therapy starts; coverage may be denied if PA not obtained
    ProductRequirements/Limits
    OPIPZA oral film (2 mg, 5 mg, 10 mg)
    Requirements/Limits = ST (step therapy); some strengths also list QL
    Control typeExample / effect
    PA New Starts for higher-tier products
    Certain Tier 5 oral oncology and specialty agents are designated PA New Starts — new therapy initiations require prior authorization
    DrugRequirement
    LYBALVI (oral tablet) — various strengths
    Requirements/Limits = PA New Starts; prior authorization required for new starts
    Agent(s)Requirements/Limits
    Eltrombopag formulations (e.g., 12.5 mg, 25 mg; 50 mg, 75 mg)
    Requirements/Limits = PA; prior authorization required prior to coverage (some strengths also list QL)
    DrugFormulary flag / implication
    Aliskiren fumarate (oral tablet 150 mg, 300 mg)
    Requirements/Limits = ST; step therapy applies before coverage
    ProductRequirement
    QELBREE oral capsule (100 mg, 150 mg, 200 mg)
    Requirements/Limits = ST; QL (30–60 EA per 30 days); step therapy required before coverage
    Agent / exampleRequirements/Limits
    EUCRISA and similar topical agents (examples in dermatology section)
    Some entries are labeled 'ST' indicating step therapy applies before coverage
    ProductFormulary flag / effect
    TALICIA oral capsule delayed release (250-12.5-10 mg)
    Requirements/Limits = ST; step therapy requirement applies

    Quantity Limits by Product

    inv-141: example: digoxin 125 mcg — 30 tablets per prescription (example provided in document).
    ExampleDigoxin 125 mcg — 30 tablets per prescription (example provided in document)
    ContextQuantity limits may be presented as tablets per prescription in addition to monthly QLs
    ReferenceSee 'Are there any restrictions on my coverage?' for digoxin example and QL explanation
    inv-142: Fentanyl citrate buccal lozenge — 120 EA per 30 days.
    Limit120 EA per 30 days
    ProductFentanyl citrate buccal lozenge (on a handle) — multiple strengths listed with PA/QL
    PA notePrior authorization indicated; PA not required for oncologists for certain strengths
    inv-143: Hydromorphone oral tablet — 360 EA per 30 days (varies by strength).
    Limit (general)360 EA per 30 days
    Strength noteLimit varies by strength (e.g., 180 EA per 30 days for 8 mg strength)
    ProductHydromorphone HCl oral tablets — QL flags shown in formulary
    inv-144: Buprenorphine transdermal patch — 4 EA per 28 days.
    Limit4 EA per 28 days (QL)
    ProductBuprenorphine transdermal patch (weekly presentations)
    TierTier = 3 for listed weekly patch strengths
    inv-145: Fentanyl transdermal patch — 15 or 30 depending on strength.
    Limit examplesFentanyl transdermal patch — QL (15 EA per 30 days) or QL (30 EA per 30 days) depending on strength
    ContextTransdermal fentanyl patch QLs vary by mcg/hr strength as shown in the formulary entries
    ReferenceSee fentanyl transdermal patch entries in table of contents for strength-specific QLs
    inv-146: fosfomycin tromethamine oral packet — 1 EA per 30 days.
    Limit1 EA per 30 days
    ProductFosfomycin tromethamine oral packet 3 gm
    NoteQuantity limit indicated in Requirements/Limits column
    inv-147: XIFAXAN ORAL TABLET 200 MG — 9 EA per 3 days.
    Limit9 EA per 3 days
    ProductXIFAXAN ORAL TABLET 200 MG
    ContextShort-period QL (per 3 days) specified for this product
    inv-148: BRIVIACT oral tablet 10 mg (example) — QL (240 EA per 30 days).
    Limit (example)QL (240 EA per 30 days) — BRIVIACT oral tablet 10 mg (example)
    ProductBRIVIACT oral tablet/solution entries show strength-specific QLs
    ActionDocument QL when submitting claims or PA requests
    inv-149: perampanel oral tablet (most strengths) — QL (30 EA per 30 days).
    LimitQL (30 EA per 30 days) — perampanel oral tablet (most strengths)
    ProductPerampanel listed with QL for multiple strengths
    TierTier = 5 for many strengths listed
    inv-150: XCOPRI oral tablet (selected packs/strengths) — QL (28-56 EA per 28-30 days depending on pack).
    Limit rangeQL (28-56 EA per 28-30 days) depending on pack/strength
    ProductXCOPRI oral tablet therapy packs and tablet strengths — pack-dependent QLs
    NoteTherapy pack QLs specified for different daily dose packs
    inv-151: FETZIMA and other listed products — QL examples shown (30 EA/30 days; 60 EA/30 days; 1 ML/30 days; 8 ML/28 days; 18 EA/84 days).
    Example QLsExamples shown include 30 EA per 30 days; 60 EA per 30 days; 1 mL per 30 days; 8 mL per 28 days; 18 EA per 84 days
    ProductsFETZIMA (levomilnacipran) and other listed products display these example QLs
    GuidanceQLs vary by product and route (EA vs mL) and are shown in Requirements/Limits
    inv-152: dihydroergotamine mesylate nasal solution — QL (8 ML per 28 days).
    LimitQL (8 ML per 28 days)
    ProductDihydroergotamine mesylate nasal solution 4 mg/mL
    ContextSpecified as mL per period rather than EA
    inv-153: VIVJOA oral capsule therapy pack — QL (18 EA per 84 days).
    LimitQL (18 EA per 84 days)
    ProductVIVJOA oral capsule therapy pack 150 mg
    NoteTherapy pack QL given per 84-day period
    inv-154: VORANIGO — QL (60 EA per 30 days for 10 mg strength).
    LimitQL (60 EA per 30 days for 10 mg strength)
    ProductVORANIGO oral tablet 10 mg
    ContextStrength-specific QL noted in Requirements/Limits
    inv-155: dasatinib (certain strengths) — QL (30 or 60 EA per 30 days depending on strength).
    LimitsQL (30 EA per 30 days) or QL (60 EA per 30 days) depending on strength
    ProductDasatinib oral tablet (certain strengths)
    NoteFormulary lists strength-dependent QLs for some oncology agents
    inv-156: NINLARO — QL (3 EA per 28 days).
    LimitQL (3 EA per 28 days)
    ProductNINLARO (oral capsule) — specified QL for certain presentations
    PA noteListed with PA New Starts for some strengths
    inv-157: erlotinib hcl oral tablet 25 mg — QL (90).
    Limit90 EA per 30 days
    ProductErlotinib HCl oral tablet 25 mg — QL shown in formulary
    TierTier = 3 noted for this product
    inv-158: NINLARO ORAL CAPSULE (2.3, 3, 4 mg) — QL (3).
    LimitQL (3 EA per 28 days)
    ProductNINLARO oral capsules (2.3 mg, 3 mg, 4 mg)
    ContextSpecified per 28-day QL in Requirements/Limits
    inv-159: RUBRACA ORAL TABLET (various strengths) — QL (120).
    LimitQL (120 EA per 30 days)
    ProductRUBRACA oral tablet (various strengths)
    ContextListed with PA New Starts and LA in many instances
    inv-160: COARTEM ORAL TABLET — 24 EA per 30 days.
    Limit24 EA per 30 days
    ProductCOARTEM oral tablet 20-120 mg
    ContextQL shown in Requirements/Limits column
    inv-161: pramipexole ER — 30 EA per 30 days.
    Limit30 EA per 30 days
    ProductPramipexole dihydrochloride ER oral tablet (various strengths)
    ContextQL and EDS flags noted in formulary
    inv-162: ropinirole ER — 60 EA per 30 days.
    Limit60 EA per 30 days
    ProductRopinirole HCl ER oral tablet extended release (various strengths)
    ContextQL indicated alongside EDS in formulary
    inv-163: ABILIFY MYCITE maintenance/starter kits — 30 EA per 30 days; 60 EA per 30 days for 2 mg pack.
    Limits30 EA per 30 days (maintenance/starter kits); 60 EA per 30 days for 2 mg pack
    ProductABILIFY MYCITE maintenance/starter kits — kit-specific QLs
    NoteListed with PA New Starts for many therapy packs
    inv-164: COBENFY starter pack — 56 EA per 28 days.
    Limit56 EA per 28 days
    ProductCOBENFY starter pack oral capsule therapy pack
    ContextPack-specific QL shown in Requirements/Limits
    inv-165: FANAPT products — QL varies (90 EA per 30 days; 60 EA per 30 days; 8-12 EA per titration period).
    LimitsVaries: 90 EA per 30 days; 60 EA per 30 days; 8-12 EA per titration period
    ProductFANAPT products — QL varies by strength/pack
    NoteSome FANAPT presentations have PA New Starts and EDS flags
    inv-166: NUPLAZID/REXULTI — QL (30 EA per 30 days).
    LimitQL (30 EA per 30 days)
    ProductsNUPLAZID oral capsule 34 mg; NUPLAZID oral tablet 10 mg; REXULTI — listed with 30 EA/30 days QL
    ContextThese CNS agents display QLs in the Requirements/Limits column
    inv-167: SECUADO TRANSDERMAL PATCH 3.8 MG/24HR — QL (30 EA per 30 days).
    LimitQL (30 EA per 30 days)
    ProductSECUADO transdermal patch 3.8 mg/24hr (and other strengths)
    PA noteListed as PA New Starts for certain strengths
    inv-168: paliperidone ER 1.5 mg — QL (90 EA per 30 days).
    LimitQL (90 EA per 30 days)
    ProductPaliperidone ER oral tablet extended release 1.5 mg
    ContextListed with EDS as well as QL
    inv-169: SECUADO patch — 30.
    Limit30 EA per 30 days
    ProductSECUADO transdermal patch (3.8 mg/24hr entry shown)
    ContextAlso referenced as QL (30) in table entries
    inv-170: VRAYLAR oral capsule — 30.
    Limit30 EA per 30 days
    ProductVRAYLAR oral capsule (selected strengths) — QL shown
    ContextFormulary lists VRAYLAR with QL (30)
    inv-171: MOUNJARO — 2 mL per 28 days (some strengths) or 2 mL per 365 days (2.5 mg strength).
    Limit2 mL per 28 days (some strengths) or 2 mL per 365 days (2.5 mg strength)
    ProductMOUNJARO subcutaneous solution auto-injector — strength-dependent QLs
    RequirementPA required; EDS applies
    inv-172: OZEMPIC — 3 mL per 28 days.
    Limit3 mL per 28 days
    ProductOZEMPIC subcutaneous solution pen-injector (various dose presentations)
    RequirementPA; EDS flag present
    inv-173: RYBELSUS — 60 EA per 365 days or 30 EA per 30 days depending on strength.
    Limit60 EA per 365 days (some strengths) or 30 EA per 30 days (others)
    ProductRYBELSUS — strength-dependent annual/monthly QLs
    RequirementPA required for listed strengths
    inv-174: TRULICITY — 2 mL per 28 days.
    Limit2 mL per 28 days
    ProductTRULICITY subcutaneous solution auto-injector — QL specified
    RequirementPA required; EDS flag present
    inv-175: OMNIPOD 5 G7 PODS — 15 EA per 30 days.
    Limit15 EA per 30 days
    ProductOMNIPOD 5 G7 PODS (GEN 5)
    ContextPODs listed with QL and EDS flags in formulary
    inv-176: OMNIPOD INTRO KIT — 1 EA per 365 days.
    Limit1 EA per 365 days
    ProductOMNIPOD 5 INTRO KIT (GEN 5) — intro kit QL
    ContextIntro kit QL shown as annual allowance in Requirements/Limits
    inv-177: VOYDEYA therapy pack — 180.
    Limit180 EA (therapy pack) — per 30 days
    ProductVOYDEYA therapy pack (50 & 100 mg) — QL noted
    RequirementPA; LA may apply
    inv-178: PYRUKYND — 56 EA per 28 days.
    Limit56 EA per 28 days
    ProductPYRUKYND oral tablet (various strengths)
    RequirementPA; LA; QL indicated
    inv-179: TAVALISSE 100 mg — 60 EA per period.
    Limit60 EA per 30 days
    ProductTAVALISSE 100 mg — QL shown
    RequirementPA; LA may apply
    inv-180: CAMZYOS ORAL CAPSULE — 30.
    Limit30 EA per 30 days
    ProductCAMZYOS oral capsule
    RequirementPA; LA; QL shown in Requirements/Limits
    inv-181: FILSPARI ORAL TABLET — 30.
    Limit30 EA per 30 days
    ProductFILSPARI oral tablet
    RequirementPA; LA; QL (30 EA per 30 days)
    inv-182: REPATHA PUSHTRONEX SYSTEM CARTRIDGE — PA New Starts; QL unspecified in excerpt.
    PA statusPA New Starts — REPATHA Pushtronex system cartridge entries
    QLQuantity limit unspecified in excerpt for REPATHA Pushtronex cartridge
    ContextREPATHA listed with PA New Starts and EDS flags in formulary
    inv-183: VERQUVO oral tablet — 30.
    Limit30 EA per 30 days
    ProductVERQUVO oral tablet (selected strengths) — QL specified
    RequirementPA and EDS noted for certain presentations
    inv-184: Various examples (30-120) for listed products.
    RangeVaries between 30–120 EA per 30 days depending on product/strength
    ExamplesIncludes lisdexamfetamine, AUSTEDO, pregabalin ER, MAYZENT — QLs shown range 30–120
    ContextMultiple CNS and neurology agents list QLs spanning this range
    inv-185: RADICAVA ORS oral suspension — 50.
    Limit50 (mL) — QL per 28 days
    ProductRADICAVA ORS oral suspension 105 mg/5 mL — QL indicated
    RequirementPA New Starts; LA may apply
    inv-186: tolvaptan (hyponatremia) — QL (30 EA per 30 days).
    LimitQL (30 EA per 30 days)
    ProductTolvaptan (hyponatremia) oral tablet — 15 mg listed with QL
    RequirementPA required; QL specified for 15 mg presentation
    inv-187: tolvaptan 15 mg — 30 EA per 30 days.
    Limit30 EA per 30 days
    ProductTolvaptan 15 mg — listed QL for hyponatremia indication
    RequirementPA required for coverage
    inv-188: LINZESS 145/72 MCG — 30 EA per 30 days.
    Limit30 EA per 30 days
    ProductLINZESS oral capsule 145/72 mcg — QL specified
    ContextListed with EDS and QL in Requirements/Limits
    inv-189: PYRUKYND ORAL TABLET — 56 EA per 28 days.
    Limit56 EA per 28 days
    ProductPYRUKYND oral tablet — QL specified in formulary
    RequirementPA; LA; QL indicated
    inv-190: VIJOICE ORAL PACKET/TABLET — 28 or 56 EA per 28 days depending on pack.
    Limit28 EA per 28 days or 56 EA per 28 days depending on pack
    ProductVIJOICE oral packet/tablet therapy packs — pack-dependent QLs
    RequirementPA; QL specified per pack in Requirements/Limits

    Site-of-Care & Dispensing Restrictions

    Note
    Note
    Note
    Note

    Definitions & Abbreviations

    inv-108: Formulary / Drug List — definition and intent.
    DefinitionFormulary / Drug List — a list of covered drugs selected by the plan; generally covered if medically necessary and filled at a network pharmacy
    PurposeRepresents prescription therapies believed necessary as part of treatment program
    ReferenceSee Evidence of Coverage for more information
    inv-109: Biosimilar / Interchangeable biosimilar — definition and substitution rules.
    DefinitionBiosimilar / Interchangeable biosimilar — biological alternative to original product; some interchangeable biosimilars may be substituted per state law
    SubstitutionInterchangeable biosimilars may be substituted at pharmacy without a new prescription depending on state laws
    ContextBiosimilars may be used in place of original biologic similar to generics
    inv-110: LA — Limited Access definition and guidance to consult Pharmacy Directory.
    DefinitionLA — Limited Access: may be available only at certain pharmacies; consult Pharmacy Directory or Member Services for details
    ActionContact Member Services or Pharmacy Directory to identify authorized dispensing locations
    ContextLA appears in Requirements/Limits column for some products
    inv-111: PA — Prior Authorization definition.
    DefinitionPA — Prior Authorization: approval required from the plan before coverage for specified drugs
    ConsequenceFailure to obtain PA may result in noncoverage or claim denial
    LocationIndicated by 'PA' in the Requirements/Limits column of the formulary
    inv-112: QL — Quantity Limit definition.
    DefinitionQL — Quantity Limit: maximum quantity allowed as noted in the Requirements/Limits column (e.g., 120 EA per 30 days)
    EnforcementPrescriptions exceeding QL may be denied unless exception or PA is approved
    ExamplesMultiple examples shown across the formulary (EA per period or mL per period)
    inv-113: ST — Step Therapy definition.
    DefinitionST — Step Therapy: requirement to try specified preferred drugs before covering an alternative
    ProcessDrugs marked 'ST' require documentation of trial/failure of preferred agents per plan rules
    LocationShown in Requirements/Limits column
    inv-114: EDS — Requirements/Limits tag appearing through the formulary segment; definition and examples.
    DefinitionEDS — Emergency/Extended Dispense Status: notation indicating extended-day supply or emergency/short-term dispensing allowances
    EffectEDS drugs on Tier 1 can be filled for 100-day supply; on Tiers 2-4 can be filled for 90-day supply
    LocationMarked as 'EDS' in Requirements/Limits column
    inv-115: BD — Billing/dispense designation used for certain formulations (e.g., depot injections).
    DefinitionBD — Billing/Dispense designation used for certain formulations (e.g., depot injections, IV solutions) indicating special billing/dispensing handling
    ContextBD entries appear in Requirements/Limits and may affect Part B vs Part D coverage determination
    ActionAdditional documentation may be required to determine setting and coverage
    inv-116: Requirements/Limits abbreviations — note that full definitions are provided elsewhere (page VI).
    NoteAbbreviations used in the Requirements/Limits column (PA, QL, ST, LA, EDS) are defined in the formulary; refer to page VI for full key
    ActionConsult page VI of the full formulary for exact definitions and administrative instructions
    ContextAbbreviations appear throughout the formulary entries and affect coverage/authorization processes

    Background & Scope

    The formulary is organized by medical condition and groups both brand and generic products under therapeutic sections. Biological products and biosimilars are discussed; the plan may add biosimilar versions and apply substitution or tiering per plan rules and applicable state law regarding interchangeability.

    Note